Related Experiment Video
Updated: Jan 13, 2026
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
1.1K
Yttrium-90 Selective Internal Radiation Therapy for Neuroendocrine Liver Metastases: An Institutional Case Series,
Xinlin Zheng1, Fang Wen2, Huan Xi1
1Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
Diagnostics (Basel, Switzerland)
|January 10, 2026
Summary
Yttrium-90 selective internal radiation therapy (Y-90 SIRT) offers promising survival and symptom improvement for neuroendocrine liver metastases (NELM). This therapy demonstrates high disease control rates with acceptable toxicity, supporting its use as a liver-directed treatment.
Area of Science:
- Hepatology
- Interventional Radiology
- Oncology
Background:
- Neuroendocrine liver metastases (NELM) present significant treatment challenges.
- Yttrium-90 selective internal radiation therapy (Y-90 SIRT) is a liver-directed treatment option for NELM.
Purpose of the Study:
- To evaluate the efficacy, safety, and symptom impact of Y-90 SIRT for NELM.
- To integrate institutional data with a systematic review and meta-analysis for comprehensive evaluation.
Main Methods:
- Retrospective analysis of 12 patients with NELM treated with Y-90 resin microspheres.
- Systematic review and meta-analysis of 43 studies (n=2221) following PRISMA guidelines.
- Pooled estimates for survival, tumor response, symptom improvement, and adverse events were calculated.
Main Results:
- Institutional cohort: Median overall survival (OS) 33.3 months, hepatic progression-free survival (HPFS) 15.3 months; 71.4% symptom improvement, no grade ≥ 3 toxicities.
- Meta-analysis: Pooled 1-year OS 82%, 1-year HPFS 64%. Pooled objective response rate (ORR) 40% (RECIST), 56% (mRECIST).
- Symptom improvement in 77% of patients; grade ≥ 3 toxicities < 5% for individual adverse events.
Conclusions:
- Y-90 SIRT demonstrates promising survival outcomes and high disease control rates in NELM.
- Significant symptom improvement is achievable with acceptable toxicity.
- Y-90 SIRT is a valuable liver-directed therapy option for patients with NELM.
